F-17

F-17 is a novel small molecule inhibitor of Fms-like tyrosine kinase 3 (FLT3), specifically designed to target both the internal tandem duplication (ITD) mutation and the D835Y point mutation in the activation loop. These mutations are common drivers of resistance in acute myeloid leukemia (AML). F-17 exhibits potent anti-leukemic activity by inhibiting the phosphorylation of FLT3 and its downstream signaling pathways, including STAT5, AKT, and ERK, which leads to cell cycle arrest and apoptosis in FLT3-mutated cells. In preclinical studies, F-17 has shown superior or comparable efficacy to established inhibitors like quizartinib (AC220) against various FLT3 mutants and has demonstrated the ability to reduce tumor growth in xenograft models.